DOCSLIB.ORG

Functional Characterization of Potential New Agents for Cancer Immunotherapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Functional Characterization of Potential New Agents for Cancer Immunotherapy Functional Characterization of Potential New Agents for Cancer Immunotherapy The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:39010116 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Functional Characterization of Potential New Agents for Cancer Immunotherapy Xiaoxu Wang A Thesis Submitted to the Faculty of The Harvard Medical School in Partial Fulfillment of the Requirements for the Degree of Master of Medical Sciences in Immunology Harvard University Boston, Massachusetts. May, 2018 Thesis Advisor: Dr. Gordon Freeman Xiaoxu Wang Functional Characterization of Potential New Agents for Cancer Immunotherapy Abstract PD-1/PD-L1 checkpoint blockade has demonstrated promise in a variety of malignancies. The blockade of T cell inhibitory molecules PD-1 and PD-L1 can rejuvenate T cells and improve tumor cell killing. However, the overall response rate of PD-1/PD-L1 immunotherapy is only about 20-30%. One promising method to improve cancer immunotherapy is combinatory immunotherapies that target new receptors/ligands regulating T cell activity, so the functional characterization of these new receptors/ligands is urgent. Due to the functional importance of the B7 superfamily in T cell activation, I studied T cell regulating functions of two poorly characterized B7 superfamily members, IgC domain-truncated CD86 and butyrophilin-like 2 (BTNL2). To study their function in a natural cell-cell interaction scenario, the murine IgC domain-truncated CD86 or murine BTNL2 was cloned and transfected into Chinese Hamster Ovary Cells that already expressed MHC Class II IAd. After co-culturing the transfectants, OVA peptide 323-339 and transgenic T cells from DO11.10 mice, I tested T cell proliferation and cytokine expression. The data suggested cell-membrane bound BTNL2 will moderately stimulate T cells and increase IFN-γ secretion significantly. Similarly, stimulatory results were also demonstrated with mBTNL2 hIgG1 fusion protein and recombinant mBTNL2 protein. The stimulatory effect of BTNL2 on T cell activation suggested that BTNL2 could be targeted as a T cell activity modulator or be a potential checkpoint ligand to be lentiviral delivered to dendritic cells as a therapy. My study indicated additional B7 proteins may be another potential target for combinatory cancer immunotherapy with PD-1/PD-L1 blockade. ii Table of Contents 1. Chapter 1: Background .........................................................................................................................................1 1.1. Checkpoint Blockade.................................................................................................................................1 1.2 ICB Response and Resistance Mechanisms..............................................................................................2 1.3 New Co-stimulatory Molecules, BTNL2 and Modified CD86.................................................................6 2. Chapter 2: Materials and Methods.....................................................................................................................11 2.1. Pre-activation of T cells............................................................................................................................11 2.2. T cell Proliferation with CHO Cells.........................................................................................................12 2.3. T cell Proliferation with Plate-Bound-Antibody....................................................................................12 2.4. Cytokine Analysis......................................................................................................................................13 2.5. Truncation Design of CD86-IgV.............................................................................................................13 2.6. Primer Design, Gene In-fusion and Vector Insertion............................................................................13 2.7. Gene Cloning............................................................................................................................................14 2.8. Cell Transfection......................................................................................................................................15 2.9. Transient Transfection.............................................................................................................................15 2.10. Cell Sorting and Subcloning...................................................................................................................15 2.11. Flow Cytometry......................................................................................................................................16 3. Chapter 3: Results ..............................................................................................................................................18 3.1. mBTNL2 Expression and Subclone Selection.........................................................................................18 3.2. T cell Stimulation with CHO Cells..........................................................................................................19 3.3. T Cell Stimulation with Plate-Bound-Antibody...................................................................................24 3.4. Initial Generation of mCD86 Constructs without the IgC Domain......................................................26 3.5. Generation and Detection of Modified mCD86 without IgC..............................................................28 4. Chapter 4: Discussion........................................................................................................................................32 4.1. Limitation and Perspectives...................................................................................................................32 4.2. Perspective for Cancer Immunotherapy................................................................................................36 5. Bibliography .......................................................................................................................................................38 iii Figures Figure 1. Hypothesis for different biological activity of IgC truncated CD86: Ability to engage cell surface CD28 but not CTLA4. In cell-cell interactions, the full length CD86, which has both IgC and IgV domain, could reach both CD28 and CTLA4. However, the IgC truncated CD86 could only reach CD28 but not CTLA4 and then results in a stronger T cell stimulation. Figure 2. Cell sorting of initial transfected population and phenotyping of mBTNL2 subclones. (A) Cell sorting of CHO-IAd+mBTNL2 cells. Double staining of mouse-IAd and mBTNL2. (B) Three mBTNL2 subclones had the indicated expression. Figure 3. T cell proliferation in the presence of mBTNL2. (A) Time schedule of naïve CD4+ T cell proliferation assay (B) Naive CD4+ T cell proliferation on day 2 and (C) Day 3. Figure 4. Naive CD4+ T cell cytokine expression analysis by Luminex. Naïve CD4+ T cell cytokine expression analysis when OVA was 1µg/mL on (A) Day 2 or (B) Day 3. Figure 5. T cell proliferation in the presence of mBTNL2. (A) Time schedule of pre-activated CD4+ T cell proliferation assay (B) Naive CD4+ T cell proliferation on day 2 Figure 6. Pre-activated CD4+ T cell cytokine expression analysis on Day 2 by Luminex. Pre- activated CD4+ T cell cytokine expression analysis when OVA was 1µg/mL. Figure 7. Naïve CD4+ T cell proliferation when co-cultured with soluble mBTNL2 hIgG1 fusion protein. Naïve CD4+ T cells were co-cultured with mBTNL2-hIgG1, 1.25µg/mL anti-CD3 and 2.5 µg/mL anti-CD28 antibody. T cell proliferation was analyzed on (A) Day 2 and (B) Day 3, separately Figure 8. Naïve CD4+ T cell proliferation when co-cultured with soluble recombinant mBTNL2. Naïve CD4+ T cell were co-cultured with rmBTNL2-His, 1.25µg/mL anti-CD3 and 5 µg/mL anti- CD28 antibody. T cell proliferation was analyzed on Day 2 Figure 9. Design of “mCD86 1st ATG, IgV+Stalk+TM+Cyto” construct. The primer “mCD86 IgV reverse” was compared with “mCD86 stalk+TM+Cyto, Forward”. The highlighted sequence was the 15-bp overlap for fusion. Figure 10. Schematic diagram of generating IgC domain truncated CD86. (A) Process of truncating IgC domain. (B) Structures of natural CD86 and modified CD86 generated in this project. Figure 11. Expression of IgC truncated mCD86. (A) Double staining of mouse-IAd and IgC truncated mCD86. (B) Expression detection of IgC truncated mCD86 or full-length m CD86 with three commercial conjugated antibodies from different clones and mCD28 or mCTLA4 fusion protein iv Tables Table 1. Primers for mCD86 cloning Table 2. Constructs of IgC truncated mCD86 v Acknowledgements I would like to give my huge and sincere thanks to my thesis advisor Dr. Gordon Freeman of the Dana-Farber Cancer Institute. Dr. Freeman is so supportive that he always teaches me experimental techniques with patience by himself. He teaches me backgrounds and knowledge of each experiment. He guides me to create ideas and design experiment to approach our thoughts. He never leaves me alone when I have troubles upon my work and gave me a lot of confidence over the
Load more

Recommended publications
  • Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease
    International Journal of Molecular Sciences Article Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease 1, 2, 1 Shaghayegh Baradaran Ghavami y, Abbas Yadegar y , Hamid Asadzadeh Aghdaei , Dario Sorrentino 3,4,*, Maryam Farmani 1 , Adil Shamim Mir 5, Masoumeh Azimirad 2 , Hedieh Balaii 6, Shabnam Shahrokh 6 and Mohammad Reza Zali 6 1 Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran; [email protected] (S.B.G.); [email protected] (H.A.A.); [email protected] (M.F.) 2 Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran; [email protected] (A.Y.); [email protected] (M.A.) 3 IBD Center, Division of Gastroenterology, Virginia Tech Carilion School of Medicine, Roanoke, VA 24016, USA 4 Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, 33100 Udine, Italy 5 Department of Internal Medicine, Roanoke Memorial Hospital, Carilion Clinic, VA 24014, USA; [email protected] 6 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran; [email protected] (H.B.); [email protected] (S.S.); [email protected] (M.R.Z.) * Correspondence: [email protected] These authors equally contributed to this study. y Received: 7 August 2020; Accepted: 27 August 2020; Published: 29 August 2020 Abstract: In inflammatory bowel diseases (IBD), the therapeutic benefit and mucosal healing from specific probiotics may relate to the modulation of dendritic cells (DCs).
    [Show full text]
  • Modulated in Intestinal Inflammation A
    BTNL2, a Butyrophilin/B7-Like Molecule, Is a Negative Costimulatory Molecule Modulated in Intestinal Inflammation This information is current as Heather A. Arnett, Sabine S. Escobar, Eva Gonzalez-Suarez, of September 28, 2021. Alison L. Budelsky, Lori A. Steffen, Norman Boiani, Ming Zhang, Gerald Siu, Avery W. Brewer and Joanne L. Viney J Immunol 2007; 178:1523-1533; ; doi: 10.4049/jimmunol.178.3.1523 http://www.jimmunol.org/content/178/3/1523 Downloaded from References This article cites 40 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/178/3/1523.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology BTNL2, a Butyrophilin/B7-Like Molecule, Is a Negative Costimulatory Molecule Modulated in Intestinal Inflammation Heather A. Arnett,1* Sabine S.
    [Show full text]
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • Expression in B Cells Receptor-Induced Regulation of B7-2
    The Journal of Immunology ␤ B Cell Receptor- and 2-Adrenergic Receptor-Induced Regulation of B7-2 (CD86) Expression in B Cells1 Adam P. Kohm,2* Afsaneh Mozaffarian,3* and Virginia M. Sanders4*† The costimulatory molecule B7-2 (CD86) is expressed on the surface of APCs, including B cells. Considering the importance of B7-2 in regulating both T and B cell function, it may be important to understand the regulatory mechanisms governing its ␤ expression. We report in this study that stimulation of the B cell receptor (BCR) and/or a neurotransmitter receptor, the 2- ␤ ␤ adrenergic receptor ( 2AR), may cooperate to regulate B cell-associated B7-2 expression in vitro and in vivo. 2AR stimulation further enhanced the level of BCR-induced B7-2 expression in B cells potentially via protein tyrosine kinase-, protein kinase A-, ␤ protein kinase C-, and mitogen-activated protein kinase-dependent mechanisms. Importantly, BCR and/or 2AR stimulation, but not histone hyperacetylation and DNA hypomethylation alone, increased B cell-associated B7-2 expression by increasing B7-2 mRNA stability, NF-␬B nuclear binding, and NF-␬B-dependent gene transcription. Thus, this study provides additional insight ␤ into the signaling intermediates and molecular mechanisms by which stimulation of the BCR and 2AR may regulate B cell- associated B7-2 expression. The Journal of Immunology, 2002, 168: 6314–6322. he growing B7 family of costimulatory molecules criti- tion increased the level of B7-2 mRNA and protein expression in cally influences the T cell-dependent Ab response. The the B cell with peak expression at 12 and 24 h, respectively (5–9).
    [Show full text]
  • Induces Antigen Presentation in B Cells Cell-Activating Factor of The
    B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
    [Show full text]
  • 1 Table S1. Outlier Loci Detected by Deepgenomescan Using
    Table S1. Outlier loci detected by DeepGenomeScan using geographic coordinates. Loci highlighted in red are detected by DeepGenomeScan but are not listed in Yang et al. (2012; Supplementary Table 4). RsID is annotated according to the dbSNP database released on 21st April, 2020. CHR BP (Grch37) BP (Grch38) rsID p.value Genes 1 1:4208918 1:4148858 rs9426495 3.8582E-104 1 1:175738168 1:175769032 rs6425357 2.0088E-105 2 2:20310668 2:20110907 rs11679737 1.2002E-111 LAPTM4A-DT 2 2:40289267 2:40062127 rs759361 5.5658E-104 SLC8A1-AS1 2 2:82495127 2:82268003 rs6726401 3.9451E-103 2 2:96660300 2:95994552 rs2579520 1.8176E-127 2 2:96672001 2:96006253 rs1917890 3.7698E-104 2 2:134333012 2:133575441 rs17816830 9.702E-105 NCKAP5 2 2:134350570 2:133592999 rs6715224 5.8745E-111 NCKAP5 2 2:134912243 2:134154672 rs2139309 1.7418E-191 MGAT5 2 2:134917005 2:134159434 rs11692586 9.2121E-151 MGAT5 2 2:134972732 2:134215161 rs11679218 0 MGAT5 2 2:134979966 2:134222395 rs1965183 5.3171E-107 MGAT5 2 2:135260071 2:134502500 rs503562 2.057E-153 TMEM163 2 2:135280039 2:134522468 rs579670 3.1477E-118 TMEM163 2 2:135285279 2:134527708 rs512375 0 TMEM163 2 2:135290221 2:134532650 rs655472 0 TMEM163 2 2:135290453 2:134532882 rs666614 0 TMEM163 2 2:135340840 2:134583270 rs842361 5.6717E-237 TMEM163 2 2:135393110 2:134635540 rs11684785 2.2164E-276 TMEM163 2 2:135430709 2:134673139 rs6745983 0 TMEM163 2 2:135469769 2:134712199 rs6747870 9.6117E-114 TMEM163 2 2:135483381 2:134725811 rs3739034 5.0357E-154 2 2:135483534 2:134725964 rs3739036 3.7269E-156 2 2:135539967 2:134782397
    [Show full text]
  • Next Generation Exome Sequencing of Paediatric Inflammatory Bowel Disease Patients Identifies Rare and Novel Variants in Candida
    Gut Online First, published on April 28, 2012 as 10.1136/gutjnl-2011-301833 Inflammatory bowel disease ORIGINAL ARTICLE Gut: first published as 10.1136/gutjnl-2011-301833 on 28 April 2012. Downloaded from Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes Katja Christodoulou,1 Anthony E Wiskin,2 Jane Gibson,1 William Tapper,1 Claire Willis,2 Nadeem A Afzal,3 Rosanna Upstill-Goddard,1 John W Holloway,4 Michael A Simpson,5 R Mark Beattie,3 Andrew Collins,1 Sarah Ennis1 < Additional materials are ABSTRACT published online only. To view Background Multiple genes have been implicated by Significance of this study these files please visit the association studies in altering inflammatory bowel journal online (http://gut.bmj. com/content/early/recent). disease (IBD) predisposition. Paediatric patients often What is already known on this subject? manifest more extensive disease and a particularly < For numbered affiliations see Genome-wide association studies have impli- end of article. severe disease course. It is likely that genetic cated numerous candidate genes for inflamma- predisposition plays a more substantial role in this group. tory bowel disease (IBD), but evidence of Correspondence to Objective To identify the spectrum of rare and novel causality for specific variants is largely absent. Dr Sarah Ennis, Genetic variation in known IBD susceptibility genes using exome Furthermore, by design, genome-wide associa- Epidemiology and Genomic sequencing analysis in eight individual cases of childhood Informatics Group, Human tion studies are limited to the study of Genetics, Faculty of Medicine, onset severe disease.
    [Show full text]
  • A Distinct Subset of Plasmacytoid Dendritic Cells Induces Activation and Differentiation of B and T Lymphocytes
    A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes Hong Zhanga, Josh D. Gregoriob, Toru Iwahoric, Xiangyue Zhanga, Okmi Choid, Lorna L. Tolentinod, Tyler Prestwooda, Yaron Carmia, and Edgar G. Englemana,1 aDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94304; bKyowa Kirin Pharmaceutical Research, La Jolla, CA 92037; cSoulage Medical Clinic, Inage-Ku Chiba-City, Chiba, 263-0005, Japan; and dStanford Blood Center, Stanford Hospital, Stanford, CA 94304 Edited by Kenneth M. Murphy, Washington University, St. Louis, MO, and approved January 10, 2017 (received for review June 29, 2016) Plasmacytoid dendritic cells (pDCs) are known mainly for their not only in peripheral blood mononuclear cells (PBMCs), but secretion of type I IFN upon viral encounter. We describe a also in bone marrow, cord blood, and tonsil, and can be gener- + + + CD2hiCD5 CD81 pDC subset, distinguished by prominent den- ated from CD34 hematopoietic progenitor cells in vitro. drites and a mature phenotype, in human blood, bone marrow, and tonsil, which can be generated from CD34+ progenitors. These Results + + CD2hiCD5 CD81 cells express classical pDC markers, as well as the CD5 and CD81 Distinguish Subsets of Human pDCs. Peripheral blood toll-like receptors that enable conventional pDCs to respond to pDCs were analyzed by flow cytometry for their expression of viral infection. However, their gene expression profile is distinct, different tetraspanin proteins based on the previous finding that and they produce little or no type I IFN upon stimulation with expression of the tetraspanin molecule CD9 distinguishes high CpG oligonucleotides, likely due to their diminished expression of and low IFNα-producing pDCs in mice (23).
    [Show full text]
  • Familial Vs. Sporadic Sarcoidosis: BTNL2 Polymorphisms, Clinical
    Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort Yves Pacheco, Alain Calender, Dominique Israël-Biet, Pascal Roy, Serge Lebecque, Vincent Cottin, Diane Bouvry, Hilario Nunes, Pascal Sève, Laurent Pérard, et al. To cite this version: Yves Pacheco, Alain Calender, Dominique Israël-Biet, Pascal Roy, Serge Lebecque, et al.. Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort. Orphanet Journal of Rare Diseases, BioMed Central, 2016, 11 (1), 10.1186/s13023-016-0546-4. hal- 01595465 HAL Id: hal-01595465 https://hal.archives-ouvertes.fr/hal-01595465 Submitted on 26 Sep 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - ShareAlike| 4.0 International License Pacheco et al. Orphanet Journal of Rare Diseases (2016) 11:165 DOI 10.1186/s13023-016-0546-4 RESEARCH Open Access Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort Yves Pacheco1,11*, Alain Calender2, Dominique Israël-Biet3, Pascal Roy4, Serge Lebecque5, Vincent Cottin6, Diane Bouvry7, Hilario Nunes7, Pascal Sève8, Laurent Pérard9, Gilles Devouassoux8, Nathalie Freymond1, Chahira Khouatra6, Benoît Wallaert10, Raphaelle Lamy2, Mad-Hélénie Elsensohn4, Claire Bardel4, Dominique Valeyre7 and GSF group Abstract Background: The occurrence of familial forms of sarcoidosis (OMIM 181100) suggests a genetic predisposition.
    [Show full text]
  • 2027.Full.Pdf
    Butyrophilin-like 2 Modulates B7 Costimulation To Induce Foxp3 Expression and Regulatory T Cell Development in Mature T Cells This information is current as of September 28, 2021. Ryan M. Swanson, Marc A. Gavin, Sabine S. Escobar, James B. Rottman, Brian P. Lipsky, Shishir Dube, Li Li, Jeannette Bigler, Martin Wolfson, Heather A. Arnett and Joanne L. Viney J Immunol 2013; 190:2027-2035; Prepublished online 28 Downloaded from January 2013; doi: 10.4049/jimmunol.1201760 http://www.jimmunol.org/content/190/5/2027 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/01/28/jimmunol.120176 Material 0.DC1 References This article cites 40 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/190/5/2027.full#ref-list-1 by guest on September 28, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Functions to Inhibit T Cell Activation BTNL2, a Butyrophilin-Like
    BTNL2, a Butyrophilin-Like Molecule That Functions to Inhibit T Cell Activation Thang Nguyen, Xikui K. Liu, Yongliang Zhang and Chen Dong This information is current as of October 2, 2021. J Immunol 2006; 176:7354-7360; ; doi: 10.4049/jimmunol.176.12.7354 http://www.jimmunol.org/content/176/12/7354 Downloaded from References This article cites 40 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/176/12/7354.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology BTNL2, a Butyrophilin-Like Molecule That Functions to Inhibit T Cell Activation1 Thang Nguyen,2* Xikui K. Liu,2† Yongliang Zhang,† and Chen Dong3† B7 family members regulate T cell activation and tolerance. Although butyrophilin proteins share sequence homology with the B7 molecules, it is unclear whether they have any function in immune responses.
    [Show full text]
  • Innate and Adaptive Signals Enhance Differentiation and Expansion of Dual-Antibody Autoreactive B Cells in Lupus
    ARTICLE DOI: 10.1038/s41467-018-06293-z OPEN Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus Allison Sang1, Thomas Danhorn 2, Jacob N. Peterson1, Andrew L. Rankin3,4, Brian P. O’Connor1,2,5,6, Sonia M. Leach2,5, Raul M. Torres1,5 & Roberta Pelanda1,5 1234567890():,; Autoreactive B cells have a major function in autoimmunity. A small subset of B cells expressing two distinct B-cell-antigen-receptors (B2R cells) is elevated in many patients with systematic lupus erythematosus (SLE) and in the MRL(/lpr) mouse model of lupus, and is often autoreactive. Here we show, using RNAseq and in vitro and in vivo analyses, signals that are required for promoting B2R cell numbers and effector function in autoimmune mice. Compared with conventional B cells, B2R cells are more responsive to Toll-like receptor 7/9 and type I/II interferon treatment, display higher levels of MHCII and co-receptors, and depend on IL-21 for their homeostasis; moreover they expand better upon T cell-dependent antigen stimulation, and mount a more robust memory response, which are characteristics essential for enhanced (auto)immune responses. Our findings thus provide insights on the stimuli for the expansion of an autoreactive B cell subset that may contribute to the etiology of SLE. 1 Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA. 2 Center for Genes, Environment and Health, National Jewish Health, Denver, CO 80206, USA. 3 Inflammation and Immunology, Pfizer Research, Cambridge, MA 02140, USA. 4 Immuno- Oncology Discovery, FivePrime Therapeutics, South San Francisco, CA 94080, USA.
    [Show full text]